Dom Meffe is one of those instant-likeables. Maybe it's because he hails from the tight-knit, friendly hometown of Pittsburgh. Maybe it's because he's just a good guy...with a big heart for his family, his employees, his clients and his business. Maybe it's because he tells good stories and draws interesting comparisons to his life and work. Maybe it's because he's someone you can relate to...who admits failures, has had tragedies in his life, and has done good. Or maybe it's because he's a survivor.
Cancer has inflicted a number of people in his family, including himself and his wife, and took his sister's life. And this is what's driven him to do what he's doing now...own and acquire a growing number of nuclear pharmacies to better diagnose and treat chronic conditions such as cancer.
In fact, only one year after founding Orlando-based Triad Isotopes, Meffe, 43, who has been a central figure in the pharma business over the past decade, is heading up what is now the fourth largest radiopharmaceutical services company in the industry. Triad has grown from 24 to 291 people with $90 million in current revenue and projections to double that in two years. That growth has come from 13 strategic M&As throughout the southeast...with many more planned over the next few years. And, Triad is among numerous specialty pharmaceutical companies (CuraScript, Axium, ACS and ICore) that have made their headquarters home in the nation's newest emerging biotech hub of Orlando.
